Literature DB >> 30527766

Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.

Leo E Akioyamen1, Jacques Genest2, Anna Chu3, Happy Inibhunu4, Dennis T Ko5, Jack V Tu5.   

Abstract

BACKGROUND: Current data from individual studies present conflicting evidence about the relationship between risk factors and cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (FH).
OBJECTIVES: We conducted a systematic review and meta-analysis to quantify the association between various CVD risk factors and CVD in FH.
METHODS: We searched MEDLINE, EMBASE, Global Health, the Cochrane Library, and PubMed for English-language studies reporting adjusted-associations between cardiovascular, behavioral, or clinical risk factors and CVD with ≥ 100 participants. We calculated pooled odds ratios (ORs) with 95% confidence intervals (CIs) for selected risk factors with random-effects meta-analysis, from which we derived attributable risk estimates.
RESULTS: We identified 27 studies representing 41,831 unique participants and 6629 CVD events. Age (OR: 1.07; 95% CI: 1.03, 1.10), male sex (OR: 1.95; 95% CI: 1.68, 2.23), hypertension (OR: 2.11; 95% CI: 1.64, 2.58), diabetes (OR: 1.95; 95% CI: 1.33, 2.57), body mass index (OR: 1.04; 95% CI: 1.03, 1.05), smoking (OR: 1.71; 95% CI: 1.30, 2.12), elevated lipoprotein(a) (OR: 1.90; 95% CI: 1.10, 2.71), low high-density lipoprotein cholesterol (OR: 1.39; 95% CI: 1.24, 1.53), and a family history of CVD (OR: 1.83, 95% CI: 1.58, 2.07) were found to be significant CVD risk factors in FH. Smoking, hypertension, and diabetes accounted for more than a quarter of CVD risk in FH individuals, whereas low-density lipoprotein cholesterol > 4.0 mmol/L accounted for 1 in 3 CVD cases. Meta-regression analyses found associations between low-density lipoprotein cholesterol (P = .045) and total cholesterol (P < .001) and CVD. Results were broadly consistent in sensitivity analyses.
CONCLUSION: Several clinical risk factors are significantly and independently associated with CVD risk in patients with FH and should be targeted for modification. These data can also inform the selection of variables for prediction models to aid in risk stratifying patients.
Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Attributable risk; Cardiovascular disease; Familial hypercholesterolemia; Meta-analysis; Risk factors; Systematic review

Mesh:

Year:  2018        PMID: 30527766     DOI: 10.1016/j.jacl.2018.10.012

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  10 in total

1.  Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects.

Authors:  Yani Yu; Lei Chen; Honghong Zhang; Zihao Fu; Qi Liu; Haijing Zhao; Yuqi Liu; Yundai Chen
Journal:  Front Cardiovasc Med       Date:  2022-06-21

2.  The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH).

Authors:  F J Kinnear; E Wainwright; J E Bourne; F E Lithander; J Hamilton-Shield; A Searle
Journal:  BMC Health Serv Res       Date:  2020-01-08       Impact factor: 2.655

3.  Reducing cardiovascular disease risk among families with familial hypercholesterolaemia by improving diet and physical activity: a randomised controlled feasibility trial.

Authors:  Fiona Jane Kinnear; Fiona E Lithander; Aidan Searle; Graham Bayly; Christina Wei; David J Stensel; Alice E Thackray; Linda Hunt; Julian P H Shield
Journal:  BMJ Open       Date:  2020-12-28       Impact factor: 2.692

4.  A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.

Authors:  Xiaoyue Ge; Tiantian Zhu; Hao Zeng; Xin Yu; Juan Li; Shanshan Xie; Jinjin Wan; Huiyao Yang; Keke Huang; Weifang Zhang
Journal:  Biomed Res Int       Date:  2021-10-31       Impact factor: 3.411

Review 5.  Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism.

Authors:  Ana M González-Lleó; Rosa María Sánchez-Hernández; Mauro Boronat; Ana M Wägner
Journal:  Nutrients       Date:  2022-04-03       Impact factor: 5.717

6.  Prevalence and Treatment of Familial Hypercholesterolemia and Severe Hypercholesterolemia in Older Adults in Ontario, Canada.

Authors:  Leo E Akioyamen; Anna Chu; Jacques Genest; Douglas S Lee; Husam Abdel-Qadir; Cynthia A Jackevicius; Patrick R Lawler; Maneesh Sud; Jacob A Udell; Harindra C Wijeysundera; Dennis T Ko
Journal:  CJC Open       Date:  2022-05-20

7.  Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician.

Authors:  Ari E Horton; Andrew C Martin; Shubha Srinivasan; Robert N Justo; Nicola K Poplawski; David Sullivan; Tom Brett; Clara K Chow; Stephen J Nicholls; Jing Pang; Gerald F Watts
Journal:  J Paediatr Child Health       Date:  2022-07-15       Impact factor: 1.929

Review 8.  Incorporating Risk Stratification Into the Practice of Pediatric Preventive Cardiology.

Authors:  Michael Khoury; Rae-Ellen W Kavey; Julie St Pierre; Brian W McCrindle
Journal:  Can J Cardiol       Date:  2020-07-14       Impact factor: 5.223

9.  Nutrition and physical activity intervention for families with familial hypercholesterolaemia: protocol for a pilot randomised controlled feasibility study.

Authors:  Fiona J Kinnear; Julian P Hamilton-Shield; David J Stensel; Graham Bayly; Aidan Searle; Alice E Thackray; Fiona E Lithander
Journal:  Pilot Feasibility Stud       Date:  2020-04-02

10.  Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography.

Authors:  Wen-Jane Lee; Han-Ni Chuang; Yi-Ming Chen; Kae-Woei Liang; Hsin Tung; Jun-Peng Chen; I-Te Lee; Jun-Sing Wang; Ching-Heng Lin; Hsueh-Ju Lin; Wayne Huey-Herng Sheu; Wen-Lieng Lee; Tzu-Hung Hsiao
Journal:  Genes (Basel)       Date:  2021-09-14       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.